H.C. Wainwright Reiterates a Buy Rating on Y-Mabs Therapeutics (YMAB)

By Austin Angelo

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Y-Mabs Therapeutics (YMABResearch Report) today and set a price target of $40.00. The company’s shares closed last Monday at $33.75, close to its 52-week high of $34.19.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -2.6% and a 43.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Currently, the analyst consensus on Y-Mabs Therapeutics is a Strong Buy with an average price target of $39.50, implying a 22.7% upside from current levels. In a report issued on November 19, Guggenheim also initiated coverage with a Buy rating on the stock with a $40.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $34.19 and a one-year low of $15.17. Currently, Y-Mabs Therapeutics has an average volume of 227.2K.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.